Observational Study
Copyright ©The Author(s) 2017.
World J Gastroenterol. Sep 14, 2017; 23(34): 6321-6329
Published online Sep 14, 2017. doi: 10.3748/wjg.v23.i34.6321
Table 1 Comparison of baseline characteristics between cirrhotic patients with and without covert hepatic encephalopathy (unimpaired)
Unimpaired, n =235CHE, n = 131P value
Sex, female/male67/16832/990.40
Age in yr46.3 ± 8.948.8 ± 7.80.009
Cause
HBV-associated180 (76.7)94 (71.8)0.31
HCV-associated8 (3.4)4 (3.1)0.86
Alcohol-associated25 (10.6)19 (14.5)0.28
Others22 (9.4)14 (10.7)0.68
Level of education
Primary school34 (14.5)45 (34.4)< 0.001
Junior high school99 (42.1)52 (39.7)0.65
Senior high school70 (29.8)33 (25.2)0.35
College degree or above32 (13.6)1 (0.8)< 0.001
Creatinine69.0 ± 16.371.3 ± 28.00.32
Venous ammonia44.3 ± 4.257.9 ± 8.9< 0.001
Albumin33.5 ± 7.726.2 ± 6.1< 0.001
High total bilirubin17.3 ± 12.317.0 ± 9.10.76
Platelets, 109/L102.6 ± 99.798.5 ± 96.70.70
International normalization ratio1.14 ± 0.121.14 ± 0.150.99
Ascites, none/mild/severe138/65/3219/30/82< 0.001
History of OHE12 (5.1)54 (41.2)< 0.001
CPC, N, A/B/C118/111/640/74/17< 0.001
MELD score14.6 ± 2.916.9 ± 6.00.02
Table 2 Comparison of clinical characteristics between 131 covert hepatic encephalopathy patients with and without overt hepatic encephalopathy development, between those with and without development of the first cirrhosis-related complications requiring hospitalization, between those with and without resolution of covert hepatic encephalopathy, and between survivors and non-survivors during follow-up
Development of OHE
Complication(s)
Death
Resolution of CHE
Yes, n = 23No, n = 108P valueYes, n = 37No, n = 94P valueYes, n = 15No, n = 116P valueYes, n = 26No, n = 105P value
Male sex19 (82.6)80 (74.1)0.3933 (89.2)66 (70.2)0.0214 (93.3)85 (73.3)0.0914 (53.8)85 (81)0.004
Age in yr46.4 ± 7.947.3 ± 8.70.5647.3 ± 8.347.2 ± 8.70.9044.7 ± 7.847.4 ± 8.60.1347.8 ± 8.249.0 ± 7.80.48
HBV-associated17 (73.9)77 (71.3)0.8027 (73.0)67 (71.3)0.859 (60)85 (73.3)0.2817 (65.4)77 (73.3)0.42
Creatinine80.5 ± 42.768.6 ± 16.80.00176.5 ± 33.268.0 ± 16.10.00195.3 ± 46.467.9 ± 16.6< 0.00172.6 ± 23.771.0 ± 29.10.80
Albumin in g/L27.2 ± 8.131.3 ± 7.80.00329.9 ± 7.931.1 ± 8.00.2329.0 ± 8.431.0 ± 7.90.2127.8 ± 5.325.8 ± 6.20.13
Total bilirubin in μmol/L23.3 ± 16.716.5 ± 10.2< 0.00122.5 ± 16.315.7 ± 8.9< 0.00129.5 ± 24.016.3 ± 9.0< 0.00115.8 ± 10.517.2 ± 8.80.47
Platelets, 109/L62.0 ± 37.2105.7 ± 102.40.00981.8 ± 105.8106.6 ± 95.90.04681.3 ± 59.2102.7 ± 100.80.29131.1 ± 109.290.35 ± 92.10.05
INR1.2 ± 0.21.1 ± 0.1< 0.0011.2 ± 0.11.1 ± 0.1< 0.0011.3 ± 0.21.1 ± 0.1< 0.0011.1 ± 0.11.1 ± 0.20.49
Ascites, none/mild/severe2/14/200712/28/680.038/21/200811/22/610.351/14/200019/29/680.039/13/200415/21/690.25
History of OHE13 (56.5)41 (38.0)0.1017 (45.9)37 (39.4)0.4912 (80)42 (36.2)0.0013 (11.5)51 (48.6)0.001
CPC, A/B/C3/18/237/56/150.066/23/834/51/90.047/8/200040/67/9< 0.0013/2/202119/71/15< 0.001
MELD score19.6 ± 4.714.9 ± 4.1< 0.00119.2 ± 4.214.3 ± 3.8< 0.00123.3 ± 5.014.8 ± 3.7< 0.00113.7 ± 4.017.7 ± 6.20.002
Complications23 (100)14 (13.0)< 0.00137 (100)0< 0.00110 (66.7)27 (23.3)< 0.001037 (35.2)< 0.001
OHE23 (100)0< 0.00123 (62.2)0< 0.0017 (46.7)16 (13.8)0.002023 (21.9)< 0.001
Mortality7 (30.4)8 (7.4)0.00210 (27.0)5 (5.3)< 0.00115 (100)0< 0.001015 (14.3)< 0.001
Table 3 Cox analysis of predictors for developing overt hepatic encephalopathy, the first cirrhosis-related complications requiring hospitalization, and mortality in 131 covert hepatic encephalopathy patients
Predictor(s)βHR95%CIP value
For developing OHEAlbumin < 30 g/L1.655.221.22-22.320.03
For developing the first cirrhosis-related complicationsCr > 133 μmol/L1.243.461.46-8.200.005
MELD score > 202.3110.124.14-24.74< 0.001
PLT < 80 × 109/L2.522.441.69-6.600.013
For mortalityCr > 133 μmol/L1.514.751.10-20.440.036